FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and is intended to determine whether an individual with inflammatory bowel disease is susceptible or resistant to anti-SMAD7 therapy. Methods are based on determining the number of CCR9 + FoxP3 + T cells, CCR9 + IFN-gamma + T-cells, CCR9 + IL17A + T-cells, FoxP3 + T-cells, IFN-gamma + T-cells and / or IL17A + T-cells in the sample from the individual. Measurement of T-cell populations is performed by flow cytometry, immunohistochemistry and / or ELISA. Methods for treatment, selection and monitoring of therapy are also described, including the determination of sensitivity to anti-SMAD7.
EFFECT: group of inventions improves the effectiveness of treatment due to the rational choice of therapy.
81 cl, 7 tbl, 9 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS TO TREAT INFLAMMATORY BOWEL CONDITION | 2008 |
|
RU2495121C2 |
| METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | 2013 |
|
RU2667960C2 |
| METHODS AND COMPOSITIONS FOR TREATING LUPUS | 2010 |
|
RU2607022C2 |
| REDUCED LEVELS OR ACTIVITY OF SYSTEMIC REGULATORY T CELLS FOR TREATING DISEASE OR CNS INJURY | 2015 |
|
RU2690670C2 |
| COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| EXPANSION OF LYMPHOCYTE WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2739770C2 |
| ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 | 2015 |
|
RU2689160C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
